Rubius Therapeutics posts $42.3M loss in Q1

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a $42.3 million loss in the first quarter of 2021, or 51 cents per diluted share, the company said Monday. The clinical-stage biopharmaceutical company posted a $48.5 million loss in the first quarter one year prior, or 60 cents per diluted share. The company owns and operates a…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.